Skip to content
Screener

EPS (Diluted) at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
-$19.55-954%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$4.68+9.3%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
-$1.36+63.9%
Revvity logo
RevvityRVTY
$0.47+2.2%
Agilent Technologies logo
Agilent TechnologiesA
$1.28+8.5%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
-$0.71+54.5%

Other financials

Income statement

See full
Revenue$32.9M+34.4%
Gross profit$12.7M+26.7%
Operating income-$49.4M-33.2%
Net income-$48.9M-63.0%

Balance sheet

See full
Cash & equivalents$44.2M-66.8%
Total debt$33.4M-6.0%
Total equity$237.2M-18.9%
Total assets$319.6M-14.9%

Cash flow

See full
Operating cash flow-$5.1M+9.5%
CapEx$96.0K-87.6%
Free cash flow-$5.2M+18.9%

Valuation

See full
Market cap$126.75M-40.8%
Enterprise value$115.96M-0.8%
P/S0.8×-0.9×

Profitability

See full
Gross margin42.7%-10.7pp
Operating margin-99.6%+64.5pp
Net margin-80.2%+61.0pp
FCF margin-53.2%-1,518pp

Returns & leverage

See full
Return on equity-46.5%-576pp
Debt / equity0.1×0.0×
Current ratio3.4×-3.3×

Where this comes from

Reported directly by Quanterix Corporation in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Quanterix Corporation’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 8:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001503274-26-000036
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income7612,6921,6535,962
Change in fair value of contingent liabilities(79)4,2731,4223,894
Other income (expense), net(239)4921,182108
Loss before income taxes(48,988)(30,086)(66,536)(53,503)
Income tax benefit5473612,986
Net loss$(48,934)$(30,013)$(66,475)$(50,517)
Net loss per common share, basic and diluted$(1.04)$(0.77)$(1.41)$(1.30)
Weighted-average common shares outstanding, basic and diluted47,16738,89347,06838,801

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Quanterix Corporation's EPS (diluted)?
Quanterix Corporation (QTRX) reported EPS (diluted) of -$1.04 in Q2 2026.
How has Quanterix Corporation's EPS (diluted) changed year-over-year?
Quanterix Corporation's EPS (diluted) decreased by 35.1% year-over-year, from -$0.77 to -$1.04.
What is the long-term trend for Quanterix Corporation's EPS (diluted)?
Over 4 years (2021 to 2025), Quanterix Corporation's EPS (diluted) has grown at a 12.9% compound annual growth rate (CAGR), from -$1.54 to -$2.50.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Quanterix Corporation's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude